Amgen strengthens rare disease drug portfolio with purchase of Horizon 22 Dec 2022

A deal valued at $27.8 billion has been struck between Amgen and Horizon Therapeutics, wherein Amgen will buy the orphan drug manufacturer.

Amgen gains thyroid eye disease treatment Tepezza and gout treatment Krystexxa in the agreement, both of which have orphan drug status under the US Food and Drug Administration designation.